[HTML][HTML] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
Simple Summary By coupling the potency of cytotoxic chemotherapy with the selectivity of
targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of …
targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of …
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.
IA Vathiotis, D Bafaloukos, KN Syrigos… - Cancers, 2023 - search.ebscohost.com
Abstract Simple Summary: By coupling the potency of cytotoxic chemotherapy with the
selectivity of targeted therapy, antibody–drug conjugates represent a unique and rapidly …
selectivity of targeted therapy, antibody–drug conjugates represent a unique and rapidly …
[HTML][HTML] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
IA Vathiotis, D Bafaloukos, KN Syrigos, G Samonis - Cancers, 2023 - ncbi.nlm.nih.gov
Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has
led to the approval of the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
led to the approval of the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.
IA Vathiotis, D Bafaloukos, KN Syrigos, G Samonis - Cancers, 2023 - europepmc.org
Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has
led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
IA Vathiotis, D Bafaloukos, KN Syrigos, G Samonis - Cancers, 2023 - search.proquest.com
Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has
led to the approval of the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
led to the approval of the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
IA Vathiotis, D Bafaloukos, KN Syrigos… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Successful targeting of HER2-activating mutations in DESTINY-Lung02 phase II study has
led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
led to the approval of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) …
[引用][C] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
IA Vathiotis, D Bafaloukos, KN Syrigos, G Samonis - Cancers (Web), 2023 - jglobal.jst.go.jp
Goto, K.; Sang-We, K.; Kubo, T.; Goto, Y.; Ahn, M.-J.; Planchard, D.; Kim, D.-W.; Yang, J.-H.;
Yang, T.-Y.; Pereira, K.; et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with …
Yang, T.-Y.; Pereira, K.; et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with …